AREV Life Sciences Global Corp. (AREVF)
OTCMKTS
· Delayed Price · Currency is USD
0.0100
0.00 (0.00%)
At close: Jan 27, 2025
AREV Life Sciences Global Income Statement
Financials in millions CAD. Fiscal year is January - December.
Millions CAD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | 2013 - 2017 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '23 Sep 30, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 | 2013 - 2017 |
| Revenue | 0.01 | 0.05 | 0.25 | 0.19 | 0.19 | - | Upgrade
|
| Revenue Growth (YoY) | -96.08% | -80.74% | 33.80% | -2.11% | - | - | Upgrade
|
| Cost of Revenue | 0.02 | 0.02 | 0.07 | - | - | 0.04 | Upgrade
|
| Gross Profit | -0.01 | 0.03 | 0.19 | 0.19 | 0.19 | -0.04 | Upgrade
|
| Selling, General & Admin | 0.24 | 1.06 | 1.08 | 0.41 | 0.77 | 0.88 | Upgrade
|
| Research & Development | 0.03 | 0.08 | 0.15 | 0.13 | 1.15 | 0.2 | Upgrade
|
| Operating Expenses | 0.18 | 1.42 | 1.83 | 0.79 | 3.22 | 1.73 | Upgrade
|
| Operating Income | -0.19 | -1.39 | -1.64 | -0.6 | -3.02 | -1.78 | Upgrade
|
| Interest Expense | -0 | -0.01 | -0.05 | -0.06 | -0.07 | -0.04 | Upgrade
|
| Currency Exchange Gain (Loss) | -0 | -0 | -0 | - | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | -0.04 | -0.03 | -0.01 | -0.05 | -0.14 | -0.04 | Upgrade
|
| EBT Excluding Unusual Items | -0.24 | -1.43 | -1.7 | -0.71 | -3.24 | -1.85 | Upgrade
|
| Impairment of Goodwill | - | - | - | - | - | -0.05 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | -0.08 | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | -0.06 | - | - | Upgrade
|
| Asset Writedown | - | - | - | -0.2 | - | -6.38 | Upgrade
|
| Other Unusual Items | 0 | -0.01 | 0.71 | - | 0.05 | 0.02 | Upgrade
|
| Pretax Income | -0.24 | -1.44 | -0.99 | -1.05 | -3.19 | -8.27 | Upgrade
|
| Net Income | -0.24 | -1.44 | -0.99 | -1.05 | -3.19 | -8.27 | Upgrade
|
| Net Income to Common | -0.24 | -1.44 | -0.99 | -1.05 | -3.19 | -8.27 | Upgrade
|
| Shares Outstanding (Basic) | 32 | 30 | 20 | 15 | 9 | 6 | Upgrade
|
| Shares Outstanding (Diluted) | 32 | 30 | 20 | 15 | 9 | 6 | Upgrade
|
| Shares Change (YoY) | 33.28% | 53.55% | 27.50% | 72.36% | 40.87% | 161.65% | Upgrade
|
| EPS (Basic) | -0.01 | -0.05 | -0.05 | -0.07 | -0.36 | -1.31 | Upgrade
|
| EPS (Diluted) | -0.01 | -0.05 | -0.05 | -0.07 | -0.36 | -1.31 | Upgrade
|
| Free Cash Flow | -0.14 | -0.31 | -1.48 | -0.33 | -0.33 | -1.1 | Upgrade
|
| Free Cash Flow Per Share | -0.00 | -0.01 | -0.08 | -0.02 | -0.04 | -0.17 | Upgrade
|
| Gross Margin | -177.06% | 59.33% | 72.60% | 100.00% | 100.00% | - | Upgrade
|
| Operating Margin | -2702.43% | -2827.74% | -644.43% | -315.34% | -1551.76% | - | Upgrade
|
| Profit Margin | -3322.81% | -2940.37% | -388.36% | -550.37% | -1639.99% | - | Upgrade
|
| Free Cash Flow Margin | -1931.00% | -633.36% | -581.17% | -174.04% | -168.90% | - | Upgrade
|
| EBITDA | -0.17 | -1.31 | -1.54 | -0.5 | -2.96 | -1.72 | Upgrade
|
| EBITDA Margin | - | - | - | -262.26% | - | - | Upgrade
|
| D&A For EBITDA | 0.02 | 0.08 | 0.1 | 0.1 | 0.07 | 0.05 | Upgrade
|
| EBIT | -0.19 | -1.39 | -1.64 | -0.6 | -3.02 | -1.78 | Upgrade
|
| Advertising Expenses | - | 0.21 | 0.19 | 0.01 | 0.04 | 0.11 | Upgrade
|
Updated Dec 8, 2023. Source: S&P Global Market Intelligence. Standard template. Financial Sources.